Residues in the stalk domain of the hendra virus g glycoprotein modulate conformational changes associated with receptor binding.
Hendra virus (HeV) is a member of the broadly tropic and highly pathogenic paramyxovirus genus Henipavirus. HeV is enveloped and infects cells by using membrane-anchored attachment (G) and fusion (F) glycoproteins. G possesses an N-terminal cytoplasmic tail, an external membrane-proximal stalk domain, and a C-terminal globular head that binds the recently identified receptors ephrinB2 and ephrinB3. Receptor binding is presumed to induce conformational changes in G that subsequently trigger F-mediated fusion. The stalk domains of other attachment glycoproteins appear important for oligomerization and F interaction and specificity. However, this region of G has not been functionally characterized. Here we performed a mutagenesis analysis of the HeV G stalk, targeting a series of isoleucine residues within a hydrophobic alpha-helical domain that is well conserved across several attachment glycoproteins. Nine of 12 individual HeV G alanine substitution mutants possessed a complete defect in fusion-promotion activity yet were cell surface expressed and recognized by a panel of conformation-dependent monoclonal antibodies (MAbs) and maintained their oligomeric structure. Interestingly, these G mutations also resulted in the appearance of an additional electrophoretic species corresponding to a slightly altered glycosylated form. Analysis revealed that these G mutants appeared to adopt a receptor-bound conformation in the absence of receptor, as measured with a panel of MAbs that preferentially recognize G in a receptor-bound state. Further, this phenotype also correlated with an inability to associate with F and in triggering fusion even after receptor engagement. Together, these data suggest the stalk domain of G plays an important role in the conformational stability and receptor binding-triggered changes leading to productive fusion, such as the dissociation of G and F.
Bishop
Kimberly A
KA
Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA. cbroder@usuhs.mil
Hickey
Andrew C
AC
Khetawat
Dimple
D
Patch
Jared R
JR
Bossart
Katharine N
KN
Zhu
Zhongyu
Z
Wang
Lin-Fa
LF
Dimitrov
Dimiter S
DS
Broder
Christopher C
CC
D000595:Amino Acid Sequence; D019943:Amino Acid Substitution; D000911:Antibodies, Monoclonal / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D002459:Cell Fusion; D002460:Cell Line; D036388:Ephrin-B2 / Q000378:metabolism*; D036389:Ephrin-B3 / Q000378:metabolism*; D045404:Hendra Virus / Q000502:physiology*; D006801:Humans; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D011485:Protein Binding; D011487:Protein Conformation; D016415:Sequence Alignment; D014759:Viral Envelope Proteins / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D036388:Ephrin-B2; D036389:Ephrin-B3; D014759:Viral Envelope Proteins; C116204:attachment protein G
J Virol. 2004 Dec;78(23):13351-5
15542686
J Virol. 2007 Jun;81(11):5893-901
17376907
Nat Rev Microbiol. 2006 Jan;4(1):23-35
16357858
Virology. 1995 Jun 1;209(2):457-69
7778280
J Virol. 2006 Jan;80(2):623-33
16378965
J Virol. 2006 Jan;80(2):891-9
16378991
J Virol. 2006 Aug;80(15):7546-54
16840334
J Virol. 1996 Sep;70(9):6112-8
8709235
Virology. 2006 Jan 5;344(1):30-7
16364733
J Virol. 1994 Sep;68(9):5411-22
8057423
J Virol. 2000 Jul;74(14):6485-93
10864661
Aust Vet J. 2000 Apr;78(4):279-80
10840578
Virology. 1995 Oct 20;213(1):190-203
7483263
Virology. 1998 Nov 25;251(2):227-33
9837786
J Virol. 2005 Jun;79(11):6690-702
15890907
J Gen Virol. 1999 Mar;80 ( Pt 3):749-753
10092015
Emerg Infect Dis. 2004 Dec;10(12):2082-7
15663842
Structure. 2005 May;13(5):803-15
15893670
Trends Microbiol. 2008 Apr;16(4):135-7
18346895
J Virol. 1999 May;73(5):3630-7
10196255
Nature. 2005 Jul 21;436(7049):401-5
16007075
J Gen Virol. 2005 Oct;86(Pt 10):2839-2848
16186240
Arch Virol Suppl. 1997;13:115-30
9413532
Emerg Infect Dis. 2006 Feb;12(2):235-40
16494748
J Virol. 1997 Sep;71(9):6287-95
9261345
Methods Mol Biol. 2004;269:309-32
15114023
J Virol. 2002 May;76(10):5051-61
11967321
Nat Struct Mol Biol. 2008 Jun;15(6):567-72
18488039
Nature. 2006 Jan 5;439(7072):38-44
16397490
Biotechniques. 1995 Sep;19(3):352-4, 356
7495543
J Virol. 2003 Oct;77(20):11040-9
14512552
J Virol. 2004 Dec;78(23):13053-61
15542657
J Virol. 2004 Apr;78(7):3733-41
15016893
J Mol Biol. 2004 Jan 30;335(5):1343-57
14729348
PLoS Pathog. 2006 Feb;2(2):e7
16477309
Med J Aust. 2006 Nov 20;185(10):562-4
17115969
J Virol. 2007 Sep;81(18):9900-10
17626104
Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):9953-8
18632560
Nat Struct Biol. 2000 Nov;7(11):1068-74
11062565
Virus Res. 2004 Feb;99(2):177-85
14749183
J Clin Virol. 2003 Apr;26(3):265-75
12637075
Emerg Infect Dis. 2007 Jul;13(7):1031-7
18214175
Curr Top Microbiol Immunol. 2007;315:133-59
17848064
Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9288-93
15964978
J Virol. 2006 May;80(10):4878-89
16641279
Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10652-7
15998730
J Virol. 2002 Dec;76(24):13028-33
12438628